Volume 58, Issue 5
Research Paper

Exploratory subgroup analysis in clinical trials by model selection

Gerd K. Rosenkranz

Corresponding Author

E-mail address: gerd.rosenkranz@meduniwien.ac.at

Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, A‐1090 Vienna Austria

Novartis Pharma AG, Novartis Campus, CH‐4002 Basel Switzerland

Corresponding author: e‐mail: gerd.rosenkranz@meduniwien.ac.at, Phone: +43‐1‐40400‐74780Search for more papers by this author
First published: 27 May 2016
Citations: 13

Abstract

The interest in individualized medicines and upcoming or renewed regulatory requests to assess treatment effects in subgroups of confirmatory trials requires statistical methods that account for selection uncertainty and selection bias after having performed the search for meaningful subgroups. The challenge is to judge the strength of the apparent findings after mining the same data to discover them. In this paper, we describe a resampling approach that allows to replicate the subgroup finding process many times. The replicates are used to adjust the effect estimates for selection bias and to provide variance estimators that account for selection uncertainty. A simulation study provides some evidence of the performance of the method and an example from oncology illustrates its use.

Number of times cited according to CrossRef: 13

  • Data-Driven and Confirmatory Subgroup Analysis in Clinical Trials, Design and Analysis of Subgroups with Biopharmaceutical Applications, 10.1007/978-3-030-40105-4_3, (33-91), (2020).
  • A critical review of graphics for subgroup analyses in clinical trials, Pharmaceutical Statistics, 10.1002/pst.2012, 19, 5, (541-560), (2020).
  • Bayesian credible subgroup identification for treatment effectiveness in time-to-event data, PLOS ONE, 10.1371/journal.pone.0229336, 15, 2, (e0229336), (2020).
  • Inference on Selected Subgroups in Clinical Trials, Journal of the American Statistical Association, 10.1080/01621459.2020.1740096, (1-18), (2020).
  • Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission, Pharmacopsychiatry, 10.1055/a-1252-2942, (2020).
  • A multiple comparison procedure for dose‐finding trials with subpopulations, Biometrical Journal, 10.1002/bimj.201800111, 62, 1, (53-68), (2019).
  • Modeling of the Type of Surgical Intervention for Breast Cancer According to Mammography Examination: Analysis of Factors, Statistics of Ukraine, 10.31767/su.3(86)2019.03.09, 86, 3, (82-89), (2019).
  • Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis, Pharmaceutical Statistics, 10.1002/pst.1919, 18, 2, (126-139), (2018).
  • Subgroup identification in clinical trials via the predicted individual treatment effect, PLOS ONE, 10.1371/journal.pone.0205971, 13, 10, (e0205971), (2018).
  • Estimates of subgroup treatment effects in overall nonsignificant trials: To what extent should we believe in them?, Pharmaceutical Statistics, 10.1002/pst.1810, 16, 4, (280-295), (2017).
  • Multiplicity issues in exploratory subgroup analysis, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1397009, (1-19), (2017).
  • Model averaging for treatment effect estimation in subgroups, Pharmaceutical Statistics, 10.1002/pst.1796, 16, 2, (133-142), (2016).
  • Comparing Approaches to Treatment Effect Estimation for Subgroups in Clinical Trials, Statistics in Biopharmaceutical Research, 10.1080/19466315.2016.1251490, 9, 2, (160-171), (2016).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.